Michael P Manns
Overview
Explore the profile of Michael P Manns including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
786
Citations
23912
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hardtke S, Yurdaydin C, Caruntu F, Curescu M, Yalcin K, Akarca U, et al.
J Viral Hepat
. 2025 Mar;
32(4):e70022.
PMID: 40087915
We analysed the frequency, severity and impact of hepatitis flares in a large Phase 2 study investigating pegylated interferon-alfa-2a (PEG-IFNa) for the treatment of hepatitis D. In the HIDIT-II study,...
2.
Manns M, Bergquist A, Karlsen T, Levy C, Muir A, Ponsioen C, et al.
Nat Rev Dis Primers
. 2025 Mar;
11(1):17.
PMID: 40082445
Primary sclerosing cholangitis (PSC) is a chronic biliary inflammation associated with periductular fibrosis of the intrahepatic and extrahepatic bile ducts leading to strictures, bacterial cholangitis, decompensated liver disease and need...
3.
Petriv N, Suo H, Hochnadel I, Timrott K, Bondarenko N, Neubert L, et al.
JHEP Rep
. 2024 Nov;
6(12):101189.
PMID: 39611128
Background & Aims: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant cause of HCC. Current treatment options for...
4.
Engel B, Diestelhorst J, Hupa-Breier K, Kirchner T, Henjes N, Loges S, et al.
Hepatol Int
. 2024 Jul;
18(4):1214-1226.
PMID: 38976227
Objective: The detection of autoantibodies is essential to diagnose autoimmune hepatitis (AIH). Particularly in children, specificity of autoantibodies decreases due to lower titers being diagnostic and being present not only...
5.
Grimsrud M, Forster M, Goeppert B, Hemmrich-Stanisak G, Sax I, Grzyb K, et al.
Hepatol Commun
. 2024 Jul;
8(7).
PMID: 38967597
Background: People with primary sclerosing cholangitis (PSC) have a 20% lifetime risk of biliary tract cancer (BTC). Using whole-exome sequencing, we characterized genomic alterations in tissue samples from BTC with...
6.
Lechel A, Ande S, Ju Z, Plentz R, Schaetzlein S, Rudolph C, et al.
EMBO Rep
. 2024 Jul;
25(8):3738.
PMID: 38951712
No abstract available.
7.
Montano-Loza A, Lytvyak E, Hirschfield G, Hansen B, Ebadi M, Berney T, et al.
J Hepatol
. 2024 May;
81(4):679-689.
PMID: 38821360
Background & Aims: Recurrent primary biliary cholangitis (rPBC) develops in approximately 30% of patients and negatively impacts graft and overall patient survival after liver transplantation (LT). There is a lack...
8.
Hintermann E, Tondello C, Fuchs S, Bayer M, Pfeilschifter J, Taubert R, et al.
J Autoimmun
. 2024 Apr;
146:103229.
PMID: 38653165
Primary sclerosing cholangitis (PSC) is an (auto)immune-mediated cholestatic liver disease with a yet unclear etiology. Increasing evidence points to an involvement of neutrophils in chronic liver inflammation and cirrhosis but...
9.
Mayerle J, Manns M
Inn Med (Heidelb)
. 2024 Mar;
65(4):293-295.
PMID: 38517508
No abstract available.
10.
Karlsen T, Rutter H, Carrieri P, Zelber-Sagi S, Engebretsen E, Hutchinson S, et al.
Lancet
. 2024 Feb;
403(10436):1522-1524.
PMID: 38359860
No abstract available.